$39.350
-0.476 (-1.21%)收盘时
CTEV 资讯
CTEV 事件
Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations
Reports Q2 revenue $257.48M, consensus $244.81M. "Claritev once again demonstrated the strength of our vision and strategy in the second quarter of 2026, delivering financial results above expectations with solid execution across the company. We are one year into a transformation program that has seen our company operate with greater clarity, alignment, and focus. This transformation is most notably highlighted by a broader portfolio of solutions, expanded vertical sales markets, heightened focus on AI as both an operational and innovation lever, and a company-wide focus on execution that is building a foundation for long term, sustainable, and ultimately faster growth," said Travis Dalton, Chairman, CEO and President of Claritev.
Company Raises FY26 Adjusted EBITDA Outlook to $620M
Consensus $993.39M. Raises FY26 adjusted EBITDA view to $620M-$620M from $605M-$615M. Backs FY26 capital expenditures view $160M-$170M. Dalton added, "This success is most clearly reflected in our bookings which were spread across solutions and verticals, with notable strength in the TPA market where we closed several seven-figure transactions. With more than $70 million in bookings through the first half of 2026, we are well on our way to achieving our full year target of $100 million which would represent 50% growth over 2025 and is a leading indicator of continued growth in 2027 and beyond."
DOJ Expands Antitrust Investigation into Claritev
DOJ expands Claritev antitrust investigation, Bloomberg reports
Claritev Shares Drop 13% to $25.93 Following Bloomberg Report
Claritev drops 13% to $25.93 following Bloomberg report
Justice Department Expands Antitrust Investigation into Claritev
The Justice Department is expanding an antitrust investigation into Claritev over allegations the company helped insurers, including UnitedHealth (UNH), CVS Health's (CVS) Aetna and Cigna (CI), illegally coordinate to reduce out-of-network reimbursement rates, Josh Sisco, Leah Nylen and Ike Swetlitz of Bloomberg report, citing people with knowledge of the matter. The Justice Department recently sent civil investigative demands to lawyers for a group of hospitals and doctor groups suing Claritev for alleged antitrust violations, sources told Bloomberg. The antitrust division is seeking information the providers are collecting during the litigation, people told the news agency. The Justice Department's inquiry involves similar allegations as the private litigation, the sources added. Shares of Claritev are down 10% to $26.92 following the report.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。